ACYCLOVIR CREAM FOR THE TREATMENT OF HERPES LABIALIS LESIONS

用于治疗唇疱疹病变的阿昔洛韦乳膏

• 批准号: 6297383
• 负责人: MARK J KUTCHER
• 金额: $ 0.02万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297383
• 关键词: Herpes simplex disease; acyclovir; clinical research; drug screening /evaluation; human subject; human therapy evaluation; microorganism disease chemotherapy; topical drug application

Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy & safety of topical acyclovir (5%) cream vs. placebo cream in treatment of herpes labialis lesions in immunocompetent subjects initiating treatment after the beginning of the next herpes labialis episode. Time to healing for classical lesions (time from vesicle formation until loss of hard crust) and lesion "abortion" (ie, episode does not progress beyond papular stage [no vesicle form]) will be examined as secondary variable. Other secondary measures will include pain, tenderness, viral shedding.

多中心、随机、双盲、安慰剂对照研究，评估外用阿昔洛韦乳膏(5%)与安慰剂乳膏治疗免疫活性受试者下一次唇疱疹发作后开始治疗的唇疱疹皮损的疗效和安全性。经典皮损的愈合时间(从水泡形成到失去硬壳的时间)和病变“流产”(即发病不会进展到丘疹阶段[无水泡形式])将被视为次要变量。其他次要措施包括疼痛、压痛、病毒脱落。